Morphosys
As of the edition of 20 October 2026, Morphosys runs 3 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Morphosys was merged in 2024; successor NOVARTIS PHARMACEUTICALS CORP.
- MORPHOSYS AG: merged in 2024; successor NOVARTIS PHARMACEUTICALS CORP
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tafasitamab | Ends 2032 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where its trials are
- Immune system: 8 trials led
- Blood and lymph: 6 trials led
- Cancer: 6 trials led